Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
FibroGen ( (FGEN) ) just unveiled an announcement.
On August 12, 2025, FibroGen, a company involved in a financing agreement with investment funds managed by Morgan Stanley Tactical Value, entered into a fourth amendment to this agreement. This amendment reduces the minimum qualified cash balance required to be held in U.S. deposit or securities accounts from $18.75 million to $15 million, potentially impacting the company’s cash management strategies and financial flexibility.
The most recent analyst rating on (FGEN) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. While there are positive developments in clinical trials and strategic transactions, these are overshadowed by the company’s poor financial health and valuation metrics. The technical analysis indicates some short-term bullish momentum, but the fundamental issues present significant risks.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
Average Trading Volume: 51,527
Technical Sentiment Signal: Sell
Current Market Cap: $37.41M
For detailed information about FGEN stock, go to TipRanks’ Stock Analysis page.